StocksFundsScreenerSectorsWatchlists
IMGN

IMGN - ImmunoGen Inc Stock Price, Fair Value and News

31.23USD Market Closed

Market Summary

IMGN
USD31.23
Market Closed

IMGN Stock Price

View Fullscreen

IMGN RSI Chart

IMGN Valuation

Market Cap

8.3B

Price/Earnings (Trailing)

-113.1

Price/Sales (Trailing)

28.91

EV/EBITDA

-35.08

Price/Free Cashflow

-41.62

IMGN Price/Sales (Trailing)

IMGN Profitability

EBT Margin

-38.01%

Return on Equity

-13.09%

Return on Assets

-8.94%

Free Cashflow Yield

-2.4%

IMGN Fundamentals

IMGN Revenue

Revenue (TTM)

287.6M

Rev. Growth (Yr)

637.72%

Rev. Growth (Qtr)

36.41%

IMGN Earnings

Earnings (TTM)

-73.5M

Earnings Growth (Yr)

139.54%

Earnings Growth (Qtr)

823.82%

Breaking Down IMGN Revenue

Last 7 days

6.7%

Last 30 days

5.3%

Last 90 days

111.6%

Trailing 12 Months

570.2%

How does IMGN drawdown profile look like?

IMGN Financial Health

Current Ratio

5.7

Debt/Equity

0

Debt/Cashflow

-94.91

IMGN Investor Care

Shares Dilution (1Y)

20.62%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023120.6M189.6M287.6M0
202292.2M89.4M95.6M108.8M
2021134.7M136.6M127.7M69.9M
202087.0M86.5M91.4M132.3M
201942.2M48.5M50.8M82.3M
2018106.8M77.0M79.5M53.4M
201757.4M89.0M89.8M115.4M
201665.2M60.0M52.8M48.6M
201578.7M85.5M87.2M56.9M
201458.0M59.9M55.9M74.1M
201334.7M35.5M48.7M76.1M
201219.9M16.4M17.9M12.9M
201118.0M19.3M18.4M21.9M
2010013.9M15.3M16.6M

Tracking the Latest Insider Buys and Sells of ImmunoGen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 12, 2024
vasconcelles michael
back to issuer
-
-
-1,327
evp r&d & medical affairs
Feb 12, 2024
arbuckle stuart a
back to issuer
-
-
-5,381
-
Feb 12, 2024
coen stacy ann
back to issuer
-
-
-73,274
svp & chief business officer
Feb 12, 2024
wallace richard john
back to issuer
-
-
-10,000
-
Feb 12, 2024
lentini renee
back to issuer
-
-
-14,723
vp & prin acctg officer
Feb 12, 2024
goldberg mark alan
back to issuer
-
-
-60,720
-
Feb 12, 2024
mitchell dean j
back to issuer
-
-
-103,000
-
Feb 12, 2024
thackray helen m.
back to issuer
-
-
-3,074
-
Feb 12, 2024
enyedy mark j
back to issuer
-
-
-584,397
chief executive officer
Feb 12, 2024
char daniel
back to issuer
-
-
-1,000
svp & chief legal officer

1–10 of 50

Which funds bought or sold IMGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 10, 2024
SOA Wealth Advisors, LLC.
sold off
-100
-1,987
-
-%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
1,838
1,838
-%
Apr 05, 2024
CWM, LLC
sold off
-100
-21,000
-
-%
Apr 05, 2024
GAMMA Investing LLC
sold off
-100
-5,629
-
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
sold off
-100
-1,250,340
-
-%
Mar 29, 2024
Kapitalo Investimentos Ltda
new
-
932,107
932,107
0.19%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
8.14
9,149
18,116
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
added
495
48,173,000
52,934,000
0.18%
Mar 14, 2024
Leo Wealth, LLC
new
-
741,724
741,724
0.08%
Mar 11, 2024
VANGUARD GROUP INC
added
4.02
366,563,000
755,095,000
0.02%

1–10 of 48

Are Funds Buying or Selling IMGN?

Are funds buying IMGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IMGN
No. of Funds

Unveiling ImmunoGen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
redmile group, llc
5.9%
16,423,922
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
9.99%
26,916,027
SC 13G/A
Feb 13, 2024
vanguard group inc
9.13%
25,466,950
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
0.35%
971,928
SC 13G/A
Jan 25, 2024
blackrock inc.
8.2%
21,823,243
SC 13G/A
Jan 22, 2024
state street corp
3.02%
8,075,671
SC 13G/A
Feb 14, 2023
redmile group, llc
8.6%
19,896,453
SC 13G/A
Feb 14, 2023
ra capital management, l.p.
9.99%
22,075,158
SC 13G/A
Feb 10, 2023
flynn james e
2.88%
6,358,314
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of ImmunoGen Inc

View All Filings
Date Filed Form Type Document
Feb 22, 2024
15-12G
15-12G
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
4
Insider Trading
Feb 12, 2024
S-8 POS
Employee Benefits Plan
Feb 12, 2024
4
Insider Trading
Feb 12, 2024
8-K
Current Report
Feb 12, 2024
S-8 POS
Employee Benefits Plan
Feb 12, 2024
S-8 POS
Employee Benefits Plan

Peers (Alternatives to ImmunoGen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

ImmunoGen Inc News

Latest updates
Defense World23 hours ago
Yahoo Canada Shine On10 Apr 202408:04 pm
InvestorPlace4 months ago

ImmunoGen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue36.4%113,425,00083,153,00049,869,00041,167,00015,375,00014,162,00038,078,00027,992,0009,210,00016,948,00015,706,00085,798,00018,189,00015,025,00013,287,00044,864,00013,281,00015,542,0008,584,00013,416,00010,928,000
Operating Expenses0.1%87,469,00087,342,00092,262,000100,726,00092,804,00075,215,00060,930,00062,546,00043,444,00044,317,00044,622,00049,279,00034,916,00033,387,00037,097,00036,370,00031,243,00056,601,00050,230,00053,839,00056,460,000
  S&GA Expenses3.8%37,744,00036,356,00040,016,00042,065,00033,623,00023,793,00016,648,00013,578,00010,297,0009,728,00010,209,0009,738,00010,231,0009,767,0008,864,0009,803,0009,208,0008,700,00010,778,0009,752,0008,347,000
  R&D Expenses-5.0%47,570,00050,077,00051,620,00058,485,00059,181,00051,422,00044,282,00048,968,00033,147,00034,589,00034,413,00039,578,00024,685,00022,921,00027,408,00026,055,00021,015,00028,559,00038,893,00043,681,00047,243,000
EBITDA Margin34.1%-0.76-1.16-1.82-2.02-1.44-1.54-1.49-1.96-0.33-0.31-0.31----------
Interest Expenses-2,539,000--------23,00024,00024,00024,00023,00024,00024,00024,00023,00024,00025,00023,000
Income Taxes-233.0%-1,166,000877,000-------------------
Earnings Before Taxes977.5%29,582,000-3,371,000--57,790,000-77,755,000-62,021,000-----9,464,000---------
EBT Margin67.5%-0.38-1.17-1.84-2.04-1.46-1.56-1.51-1.99-0.35-0.32-0.33----------
Net Income823.8%30,748,000-4,248,000-41,014,000-59,008,000-77,755,000-62,021,000-24,145,000-37,172,000-37,339,000-30,741,000-34,051,00031,388,000-22,374,000-24,298,000-29,088,0004,814,000-21,750,000-43,446,000-43,751,000-41,799,000-46,807,000
Net Income Margin73.4%-0.26-0.96-1.99-2.05-2.10-1.80-1.40-1.99-0.55-0.41-0.37----------
Free Cashflow102.1%1,416,000-66,819,000-73,928,000-60,447,000-64,812,000-64,198,000-41,709,000-46,243,000-35,167,000-43,926,000-45,514,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets15.1%822714288349359422482526297301346355248270299235254288324295340
  Current Assets14.6%767669244304330394457500271274320324219241271209226259290279323
    Cash Equivalents5.9%606572201275310374438479246240283479188220247176204240270262303
  Inventory70.0%5.003.001.00-----------------2.00
  Net PPE17.3%4.004.004.004.004.004.004.005.005.005.005.006.006.006.006.007.009.0010.0014.0013.0013.00
Liabilities16.6%261223166193181172175200220233252266291294303311340356352284293
  Current Liabilities43.7%13594.0010212210487.0084.0010111212013412210091.0086.0077.0088.0075.0061.0071.0070.00
  Long Term Debt--------------2.002.002.002.002.002.002.002.00
    LT Debt, Current----------1.002.002.002.00--------
    LT Debt, Non Current--------------2.002.002.002.002.002.002.002.00
Shareholder's Equity14.4%56249112215617825030632677.0068.0094.0090.00-------11.0047.00
  Retained Earnings-0.5%-1,708-1,700-1,735-1,694-1,600-1,557-1,500-1,471-1,400-1,396-1,400-1,331-1,400-1,300-1,300-1,287-1,292-1,270-1,227-1,183-1,141
  Additional Paid-In Capital1.8%2,2682,2281,8551,8481,8111,8051,8001,7951,5091,4631,4581,4191,3191,3151,3111,2101,2051,2011,1981,1931,187
Shares Outstanding6.9%266249226226253253253220201200199176---------
Float------990---1,314---799---321---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations104.2%2,770-66,741-73,719-60,199-64,210-63,991-41,402-45,874-35,042-43,879-44,6218,535-30,647-28,193-28,315-32,557-35,000-31,01310,203-41,285-39,856
  Share Based Compensation5.9%7,8747,4337,06710,7535,4824,9734,4076,4333,4773,7423,8233,8673,8783,4543,1223,2283,6262,2065,1074,5254,410
Cashflow From Investing-1635.9%-1,354-78.00-209-248-602-207-307-369-125-47.00-893-102-771-23.001,4052,229-407-228-2,127-1,026-2,093
Cashflow From Financing-92.7%32,132437,55739.0026,074449411620279,23241,39034434,77897,20612942397,9842,06273.0067068.001,35896.00

IMGN Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 113,425$ 15,375$ 246,447$ 67,615
Cost and operating expenses:    
Cost of sales2,155 3,690 
Research and development47,57059,181149,267154,885
Selling, general and administrative37,74433,623114,11674,064
Total cost and operating expenses87,46992,804267,073228,949
Income (loss) from operations25,956(77,429)(20,626)(161,334)
Interest income7,3831,53914,7752,183
Interest expense on term loan(2,539) (5,857) 
Non-cash interest expense on liability related to the sale of future royalties and term loan(1,054)(867)(2,986)(3,194)
Other (expense) income, net(164)(998)(109)(1,576)
Net loss before income taxes29,582(77,755)(14,803)(163,921)
Income tax benefit(1,166) (289) 
Net loss$ 30,748$ (77,755)$ (14,514)$ (163,921)
Net income (loss) per common share - basic (Note B)$ 0.10$ (0.31)$ (0.05)$ (0.65)
Net income (loss) per common share - diluted (Note B)$ 0.10$ (0.31)$ (0.05)$ (0.65)
Basic weighted average common shares outstanding (in shares)273,341253,511265,265253,371
Diluted weighted average common shares outstanding (in shares)287,590253,511265,265253,371
License and milestone fees    
Revenues:    
Total revenues$ 51$ 7,382$ 15,122$ 45,247
Non-cash royalty revenue related to the sale of future royalties    
Revenues:    
Total revenues7,355$ 7,99317,93621,537
Research and development support    
Revenues:    
Total revenues855 1,310$ 831
Product revenue, net    
Revenues:    
Total revenues$ 105,164 $ 212,079 

IMGN Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2023
Dec. 31, 2022
ASSETS  
Cash and cash equivalents$ 605,535,000$ 275,138,000
Accounts receivable130,694,00012,596,000
Unbilled receivable3,026,0001,531,000
Non-cash royalty receivable3,438,0003,851,000
Inventory5,495,000 
Prepaid and other current assets18,712,00011,005,000
Total current assets766,900,000304,121,000
Property and equipment, net of accumulated depreciation4,431,0004,377,000
Operating lease right-of-use assets8,338,00010,231,000
Long-term inventory28,273,00016,196,000
Other assets14,159,00014,011,000
Total assets822,101,000348,936,000
LIABILITIES AND SHAREHOLDERS' EQUITY  
Accounts payable24,853,00045,353,000
Accrued compensation15,155,00011,111,000
Other accrued liabilities43,571,00038,783,000
Current portion of liability related to the sale of future royalties, net of deferred financing costs of $128 and $162, respectively9,437,0008,659,000
Current portion of operating lease liability4,458,0004,096,000
Current portion of deferred revenue37,186,00013,856,000
Total current liabilities134,660,000121,858,000
Senior secured term loan, net72,113,000 
Deferred revenue, net of current portion26,718,00036,355,000
Operating lease liability, net of current portion7,759,00011,148,000
Liability related to the sale of future royalties, net of current portion and deferred financing costs of $111 and $205, respectively16,455,00023,449,000
Other long-term liabilities2,800,000300,000
Total liabilities260,505,000193,110,000
Commitments and contingencies (Note K)
Shareholders' equity:  
Preferred stock, $.01 par value; authorized 5,000 shares; 22 and 0 shares issued and outstanding as of each of September 30, 2023 and December 31, 2022, respectively
Common stock, $.01 par value; authorized 600,000 shares; 265,842 and 220,046 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively2,435,0002,260,000
Additional paid-in capital2,267,747,0001,847,638,000
Accumulated deficit(1,708,586,000)(1,694,072,000)
Total shareholders' equity561,596,000155,826,000
Total liabilities and shareholders' equity$ 822,101,000$ 348,936,000
IMGN
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEimmunogen.com
 INDUSTRYBiotechnology
 EMPLOYEES277

ImmunoGen Inc Frequently Asked Questions


What is the ticker symbol for ImmunoGen Inc? What does IMGN stand for in stocks?

IMGN is the stock ticker symbol of ImmunoGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmunoGen Inc (IMGN)?

As of Tue Feb 13 2024, market cap of ImmunoGen Inc is 8.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMGN stock?

You can check IMGN's fair value in chart for subscribers.

What is the fair value of IMGN stock?

You can check IMGN's fair value in chart for subscribers. The fair value of ImmunoGen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ImmunoGen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ImmunoGen Inc a good stock to buy?

The fair value guage provides a quick view whether IMGN is over valued or under valued. Whether ImmunoGen Inc is cheap or expensive depends on the assumptions which impact ImmunoGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMGN.

What is ImmunoGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 13 2024, IMGN's PE ratio (Price to Earnings) is -113.1 and Price to Sales (PS) ratio is 28.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ImmunoGen Inc's stock?

In the past 10 years, ImmunoGen Inc has provided 0.077 (multiply by 100 for percentage) rate of return.